🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congratulations PCF-YI class of 2024 PCF Science Prostate Cancer Foundation #PCFRetreat24 #prostatecancer

Misha Beltran gives a wonderful Felix Feng Special Lecture #PCFRetreat24. You can’t make this stuff up. Felix Feng has worked on almost *everything* relevant to #ProstateCancer in the past 15 years. Unbelievable impact

To the amazing visionary scientist, mentor, friend, and guru Felix Feng Thank you! Prostate Cancer Foundation PCF Science #pcfretreat24

uPAR-targeting antibodies provide a new antibody-based PET imaging candidate for pancreatic cancer imaging as well as chemotherapy-induced senescence. ow.ly/MFrz50TKWX4 #NuclearMedicine #PETscan #PancreaticCancer Edwin Pratt Jason Lewis Radiochem MSK

Our 31st Annual PCF Scientific Retreat was a huge success. The resulting State of the Science Report highlights the latest in prostate cancer research, from underlying biology, to innovations in treatment, to survivorship: pcf.org/stateofscience… #MedEd #MedX

MSK researchers are confronting a different and deadlier form or #prostatecancer called neuroendocrine prostate cancer (NEPC), which usually arises when #adenocarcinoma develops resistance to treatments such as certain hormonal therapies. “No other program in the country really

Our review article discussing HER3 is now out in Nature Reviews Clinical Oncology - we explore the mechanistic role of HER3 in oncogenesis as well as the most relevant therapeutic agents targeting HER3. Helena Yu Memorial Sloan Kettering Cancer Center nature.com/articles/s4157…

Very nice review on HER3 targeting by Helena Yu and colleagues. A bispecific HER3xHER2 mAb was recently approved in thoracic oncology. However, despite many strategies studied to date, only anti-HER3 ADCs have shown benefit in breast oncology to date. nature.com/articles/s4157…

🧪HER3 as a treatment target in cancer NatureRevClinOncol ✅Zenocutuzumab: HER3 × HER2 bispecific antibody ➡️NRG1 fusion: high-affinity HER3 ligand neuregulin 1 ✅FDA approval in NSCLC and pancreatic cancer 👉doi.org/10.1038/s41571… OncoAlert #cancer #oncology #MedX

Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC—A Real-World Case Series: Case Report out on JTO jto.org/article/S1556-… Small cell #LungCancer 🫁 ( #SCLC ) has the highest propensity for brain metastases among all cancers, and

The U.S. FDA has expanded approval for 177Lu-PSMA-617 (Pluvicto), a treatment for patients with #prostatecancer, based on results from a phase 3 trial led by researchers at MSK. More patients can now benefit from the treatment. “This type of precision medicine is a game changer

1/ 🧬 HER3 lacks strong kinase activity... But it's a powerful oncogenic driver. 📈 Overexpressed across many tumors 💥 Implicated in drug resistance 🔗 Now officially targetable in NRG1 fusion cancers #Oncology #HER3 #TargetedTherapy doi.org/10.1038/s41571…

Huge congratulations to Dr. Sal Tendler and his graduation from the Advanced Oncology Clinical Fellowship, Department of Internal Medicine Memorial Sloan Kettering Cancer Center. Next step - joining the faculty on the GU Service (and still hanging around the lab)